Ropeginterferon Alfa-2b Experience with Ph negative myeloproliferative neoplasm Treatment at Department of Internal Medicine –Hematology and Oncology in Brno

Abstract

Background: Ropeginterferon alfa-2b evinced efficacy and safety in patients with polycythemia vera in PROUD-PV and CONTINUATION-PV multicentric randomized studies.  These studies recorded the superior effect of ropeginterferon alfa-2b in achieving hematologic and molecular remission during the fourth and fifth year of therapy.

Patients and Methods: A total of 14 Ph-MPN patients treated with ropeginterferon alfa-2b at our Dept. of Internal Medicine – Hematology and Oncology were analyzed from May 2020 to July 2022. Therapy duration, dosing, effect, and tolerance were evaluated.

Results: Therapy median duration was 266 days. 14 patients in total were treated; 11 of them had polycythemia vera (79%), 2 had essential thrombocythemia (14%), and one patient endured secondary myelofibrosis after polycythemia vera (7%).  Ropeginterferon alfa 2-b median dose was 150ug. Complete hematological remission was attained in 11 (79%) patients. Two patients (14%) had to discontinue treatment. During therapy, six patients (43%) suffered adverse events; only one patient (7%) developed a thromboembolic event.

Conclusion: With our primary experience, we have recognized the promising efficacy of ropeginterferon alfa 2-b on hematocrit control and an excellent tolerance among patients.